Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 18/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 17/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2203419 | 0.82 | OPRL1 (0.66) | OPRM1OPRL1OPRK1 | |
| SCHEMBL2204342 | 0.81 | OPRM1 (0.56) | OPRM1OPRL1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2203926 | 0.79 | OPRM1 (0.52) | OPRM1OPRL1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4344782 | 0.77 | SLC6A4 (0.62) | OPRM1OPRL1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3411008 | 0.75 | OPRM1 (0.54) | OPRM1OPRL1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27826344 | 0.74 | OPRL1 (0.50) | OPRM1OPRL1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5160213 | 0.74 | OPRM1 (0.50) | OPRM1OPRL1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL526471 | 0.74 | OPRM1 (0.52) | OPRM1OPRL1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4344633 | 0.73 | OPRL1 (0.49) | OPRM1OPRL1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22112097 | 0.73 | OPRM1 (0.49) | OPRM1OPRL1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278319-B2 | Substituted spiroamine compounds | GRUENENTHAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| EP-2344457-A1 | SUBSTITUTED SPIROAMINES | Grünenthal GmbH (DE) | 2011-07-20 | — | — | EP | disclosed |
| US-20100113417-A1 | Substituted Spiroamine Compounds | GRUENENTHAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| WO-2010049146-A1 | SUBSTITUTED SPIROAMINES | Grünenthal GmbH (DE) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113417-A1 | Substituted Spiroamine Compounds | BDKRB1, BDKRB2, REN | OPRM1 82/4885OPRL1 12/4885SLC6A2 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.